News

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform pediatric progressive myopia. Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long. The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting

(Bloomberg) -- Impossible Foods Inc. obtained a second food-safety clearance in the European Union, bringing the company closer to selling its plant-based burger in the world’s biggest market for alternative meats.Most Read from BloombergUnder Trump, Prepare for New US Transportation PrioritiesZimbabwe City of 700,000 at Risk of Running Dry by Year-EndSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and EmissionsThe Europ

RPM devices are poised to become a cornerstone of healthcare for patients around the globe.

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease vaccine like therapy.

Warren Buffett is stockpiling cash. His Berkshire Hathaway holding company continued to sell more than it bought in the third quarter when it offloaded a quarter of its stake in Apple, regulatory filings revealed Thursday.

Two of the locations will be in the Northeast and a third is in Florida

Shares in Palantir Technologies Inc were up more than 6% on Friday, hitting a record high, after it announced late on Thursday that it would list on the Nasdaq and expects eligibility to join the Nasdaq 100 index. The data analytics software company said it would switch its stock listing from the New York Stock Exchange and begin trading on Nasdaq on Nov. 26. If it is included in the Nasdaq 100 index, this would mean that "anyone who uses the Nasdaq index as their benchmark will have to buy PLTR," said Kenny Polcari, Chief Market Strategist for SlateStone Wealth in a research note.